1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Sutro Biopharma, Inc. - Product Pipeline Review - 2016

Sutro Biopharma, Inc. - Product Pipeline Review - 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 34 pages

Sutro Biopharma, Inc. - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Sutro Biopharma, Inc. - Product Pipeline Review - 2016’, provides an overview of the Sutro Biopharma, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sutro Biopharma, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Sutro Biopharma, Inc.
- The report provides overview of Sutro Biopharma, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Sutro Biopharma, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Sutro Biopharma, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Sutro Biopharma, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sutro Biopharma, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sutro Biopharma, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents

Sutro Biopharma, Inc. - Product Pipeline Review - 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Sutro Biopharma, Inc. Snapshot 6
Sutro Biopharma, Inc. Overview 6
Key Information 6
Key Facts 6
Sutro Biopharma, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Sutro Biopharma, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Sutro Biopharma, Inc. - Pipeline Products Glance 11
Sutro Biopharma, Inc. - Early Stage Pipeline Products 11
Discovery Products/Combination Treatment Modalities 11
Sutro Biopharma, Inc. - Drug Profiles 12
Monoclonal Antibodies for Cancer 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Monoclonal Antibodies for Oncology 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Monoclonal Antibody Conjugate for Oncology 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Monoclonal Antibody Conjugates 1 for Oncology 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Monoclonal Antibody Conjugates 2 for Oncology 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Monoclonal Antibody for Cancer 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Monoclonal Antibody to Antagonize CTLA4 for Oncology 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Monoclonal Antibody to Inhibit LAG3 for Oncology 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Monoclonal Antibody to Inhibit PD-1 for Cancer 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Monoclonal Antibody to Inhibit PD-L1 for Oncology 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Monoclonal Antibody to Inhibit TIM3 for Oncology 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Monoclonal Antibody to Target CD3 for Neuroblastoma 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Monoclonal Antibody to Target GD2 for Melanoma 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Monoclonal Antibody to Target GD2 for Neuroblastoma 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Monoclonal Antibody to Target GD2 for Osteosarcoma 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Synthetic Peptide for Undisclosed Indication 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Sutro Biopharma, Inc. - Pipeline Analysis 28
Sutro Biopharma, Inc. - Pipeline Products by Target 28
Sutro Biopharma, Inc. - Pipeline Products by Molecule Type 29
Sutro Biopharma, Inc. - Pipeline Products by Mechanism of Action 30
Sutro Biopharma, Inc. - Recent Pipeline Updates 31
Sutro Biopharma, Inc. - Locations And Subsidiaries 32
Head Office 32
Other Locations and Subsidiaries 32
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 33
Expert Panel Validation 33
Contact Us 33
Disclaimer 34

List of Tables
Sutro Biopharma, Inc., Key Information 6
Sutro Biopharma, Inc., Key Facts 6
Sutro Biopharma, Inc. - Pipeline by Indication, 2016 8
Sutro Biopharma, Inc. - Pipeline by Stage of Development, 2016 9
Sutro Biopharma, Inc. - Monotherapy Products in Pipeline, 2016 10
Sutro Biopharma, Inc. - Discovery, 2016 11
Sutro Biopharma, Inc. - Pipeline by Target, 2016 28
Sutro Biopharma, Inc. - Pipeline by Molecule Type, 2016 29
Sutro Biopharma, Inc. - Pipeline Products by Mechanism of Action, 2016 30
Sutro Biopharma, Inc. - Recent Pipeline Updates, 2016 31
Sutro Biopharma, Inc., Other Locations 32

List of Figures
Sutro Biopharma, Inc. - Pipeline by Indication, 2016 8
Sutro Biopharma, Inc. - Pipeline by Target, 2016 28
Sutro Biopharma, Inc. - Pipeline by Molecule Type, 2016 29
Sutro Biopharma, Inc. - Pipeline Products by Mechanism of Action, 2016 30

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Galena Biopharma, Inc. (GALE) - Financial and Strategic SWOT Analysis Review

Galena Biopharma, Inc. (GALE) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2016
  • by Global Data

Summary Galena Biopharma, Inc. (Galena) is a biotechnology company that discovers, develops and commercializes therapies for the treatment of unmet medical needs, and advance care. Its pipeline products ...

ARCA biopharma, Inc. (ABIO) - Financial and Strategic SWOT Analysis Review

ARCA biopharma, Inc. (ABIO) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2016
  • by Global Data

Summary ARCA biopharma, Inc. (ARCA), formerly Nuvelo, Inc., is a biopharmaceutical company. The company focuses on the development of genetically targeted therapies for cardiovascular diseases. Its product ...

Can-Fite BioPharma Ltd. (CFBI) - Financial and Strategic SWOT Analysis Review

Can-Fite BioPharma Ltd. (CFBI) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • October 2016
  • by Global Data

Summary Can-Fite BioPharma Ltd. (Can-Fite) is a biopharmaceutical company that concentrates on the discovery and clinical development of drugs. The company's pipeline product portfolio comprise CF101, ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.